Site-specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity

British Journal of Pharmacology

Volumn 163, Issue 2, 2011, Pages 399-412

  Gong, Nian ^a   Ma, Ai Niu ^a   Zhang, Li Jie ^b   Luo, Xiao Su ^b   Zhang, Yin Hui ^b   Xu, Michael ^b   Wang, Yong Xiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b PegBio Co Ltd   (China)

Author keywords

cAMP; exenatide; glucoregulation; site specific PEGylation

Indexed keywords

CYCLIC AMP; EXENDIN 4; GLUCAGON LIKE PEPTIDE; MACROGOL; MALEIMIDE; PB 102; PB 105; PB 106; PB 107; PB 108; PB 110; PB 111; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELL LEVEL; CELL STRAIN; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG STRUCTURE; DRUG SYNTHESIS; GLYCEMIC CONTROL; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PEGYLATION; PRIORITY JOURNAL; RAT; SPECIES COMPARISON; STREPTOZOCIN DIABETES;

AMINO ACID SEQUENCE; ANIMALS; BLOOD GLUCOSE; CYCLIC AMP; CYSTEINE; DIABETES MELLITUS, EXPERIMENTAL; HYPOGLYCEMIC AGENTS; MALE; MICE; MOLECULAR SEQUENCE DATA; PC12 CELLS; PEPTIDES; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; TYROSINE; VENOMS;

EID: 79954469776     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01227.x     Document Type: Article

References (49)

1. Baggio L, Kieffer TJ, Drucker DJ, (2000). Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, regulates fasting glycemia and nonenteral glucose clearance in mice. Endocrinology 141: 3703-3709.
2. Bailon P, Won CY, (2009). PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 6: 1-16.
3. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, et al,. (2001). Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12: 195-202. (Pubitemid 32235471)
4. Bowen S, Tare N, Inoue T, Yamasaki M, Okabe M, Horii I, et al,. (1999). Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp Hematol 27: 425-433.
5. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, (2004). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylureatreated patients with type 2 diabetes. Diabetes Care 27: 2628-2635. (Pubitemid 39441462)
6. Caliceti P, Veronese FM, (2003). Pharmacokinetic and biodistribution properties of poly(ethylene glycol) protein conjugates. Adv Drug Del Rev 55: 1261-1277. (Pubitemid 37464561)
7. Chapman AP, (2002). PEGylated antibodies and antibody fragments for improved therapy: a review. Adv Drug Deliv Rev 54: 531-545. (Pubitemid 34615547)
8. Chapman AP, Antoniw P, Spitali M, West S, Stephens S, King DJ, (1999). Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol 17: 780-783. (Pubitemid 29365106)
9. Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG, (2006). Investigation of exenatide elimination and its in vivo and in vitro degradation. Curr Drug Metab 7: 367-374.
10. Cuddihy R, Rosenstock J, Henry R, Alessi T, Luskey K, (2010). Comparing ITCA 650, continuous subcutaneous delivery of exenatide via DUROS® device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes. European Association for the Study of Diabetes (EASD) 46th Annual Meeting: Abstract 78.
11. DeFronzo R, Ratner R, Han J, Kim D, Fineman M, Baron A, (2005). Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1083-1091. (Pubitemid 40616617)
12. Doyle ME, Theodorakis MJ, Holloway HW, Bernier M, Greig NH, Egan JM, (2003). The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept 114: 153-158. (Pubitemid 36773880)
13. Edwards CMB, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, et al,. (2001). Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281: 155-161.
14. Egan JM, Clocquet AR, Elahi D, (2002). The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab 87: 1282-1290. (Pubitemid 36121100)
15. Egan JM, Meneilly GS, Elahi D, (2003). Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am J Physiol Endocrinol Metab 284: E1072-E1079. (Pubitemid 36617451)
16. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP, (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267: 7402-7405.
17. Fabunmi R, Nielsen LL, Quimbo R, Schroeder B, Misurski D, Wintle M, et al,. (2009). Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glarging. Curr Med Res Opin 25: 777-786.
18. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, et al,. (2002). Gluagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143: 4397-4408. (Pubitemid 35239574)
19. Fishburn CS, (2008). The pharmacology of PEGylation: balancing PD with PK to generate Novel Therapeutics. J Pharm Sci 97: 4167-4183.
20. Fontana A, Spolaore B, Mero A, Veronese FM, (2008). Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase. Adv Drug Deliv Rev 60: 13-28. (Pubitemid 350181164)
21. French AC, Thompson AL, Davis BG, (2009). High-purity discrete PEG-oligomer crystals allow structural insight. Angew Chem Int Ed Engl 48: 1248-1252.
22. Gong N, Zhang LJ, Ma AN, Huang JL, Xu M, Wang YX, (2009). Pharmacokinetic and pharmacodynamic evaluations of site-specific PEGylated exenatide analogs as long-acting glucoregulatory agents. Chin Pharmacol Bull 25: 140.
23. Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, et al,. (1999). Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42: 45-50. (Pubitemid 29039736)
24. Hargrove DM, Kendall ES, Reynolds JM, Lwin AN, Herich JP, Smith PA, et al,. (2007). Biological activity of AC3174, a peptide analog of exendin-4. Regul Pept 141: 113-119. (Pubitemid 46482688)
25. Holst JJ, (2007). The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439. (Pubitemid 350041474)
26. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, et al,. (2005). Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083-1091. (Pubitemid 40616617)
27. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, et al,. (2007). Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30: 1487-1493. (Pubitemid 46871159)
28. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, et al,. (2003). Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88: 3082-3089. (Pubitemid 36877476)
29. Kolterman OG, Kim DD, Shen L, Ruggles JA, Nielsen LL, Fineman M, et al,. (2005). Pharmacokinetics, pharmacodynamics, and safety of a range of subcutaneous exenatide (exendin-4) doses in subjects with type 2 diabetes. Am J Health Syst Pharm 62: 173-181.
30. Lopez de Maturana R, Willshaw A, Kuntzsch A, Rudolph R, Donnelly D, (2003). The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1. J Biol Chem 278: 10195-101200.
31. Malendowicz LK, Nowak KW, Zyterska A, Nussdorfer GG, Macchi C, Nowak M, (2001). Exendin-4, a GLP-1 receptor agonist, stimulates entero-insular axis in the rat, through a mechanism involving adrenal medulla. Biomed Res 22: 295-297.
32. Manjula BN, Tsai A, Upadhya R, Perumalsamy K, Smith PK, Malavalli A, et al,. (2003). Site-specific PEGylation of hemoglobin at Cys-93(beta): correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain. Bioconjug Chem 14: 464-472. (Pubitemid 36348671)
33. Mann R, Nasr N, Hadden D, Sinfield J, Abidi F, Al-Sabah S, et al,. (2007). Peptide binding at the GLP-1 receptor. Biochem Soc Trans 35: 713-716. (Pubitemid 47310351)
34. Mann RJ, Nasr NE, Sinfield JK, Paci E, Donnelly D, (2010). The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4. Br J Pharmacol 160: 1973-1984.
35. Montrose-Rafizadeh C, Yang H, Rodgers BD, Beday A, Pritchette LA, Eng J, (1997). High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. J Biol Chem 272: 21201-21206. (Pubitemid 27373982)
36. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W, (1993). Normalization of fasting hyperlycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type-2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744. (Pubitemid 23218642)
37. Neidigh JW, Fesinmeyer RM, Prickett KS, Andersen NH, (2001). Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states. Biochemistry 40: 13188-13200. (Pubitemid 33043533)
38. Parkes D, Jodka C, Smith P, Nayak S, Rinehart L, Gingerich R, et al,. (2001). Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Drug Dev Res 53: 260-267. (Pubitemid 33029654)
39. Perez-Tilve D, Gonzalez-matias L, Aulinger BA, Alvarez-Crespo M, Gil-Lozano M, Alvarez E, et al,. (2010). Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system. Am J Physiol Endocrinol Metab 298: E1088-E1096.
40. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KTY, Egan JM, et al,. (2002). A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 300: 958-966. (Pubitemid 34165002)
41. Qualmann C, Nauck MA, Holst JJ, Qrskov C, Creutzfeldt W, (1995). Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 32: 13-16.
42. Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN, (2005). A long-acting, highly potent interferon-2 conjugate created using site-specific PEGylation. Bioconjugate Chem 16: 200-207. (Pubitemid 40129694)
43. Runge S, Schimmer S, Oschmann J, Schiodt CB, Knudsen SM, Jeppesen CB, et al,. (2007). Differential structural properties of GLP-1 and exendin-4 determine their relative affinity for the GLP-1 receptor N-terminal extracellular domain. Biochemistry 46: 5830-5840. (Pubitemid 46764131)
44. Runge S, Thogersen H, Madsen K, Lau J, Rudolph R, (2008). Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J Biol Chem 283: 11340-11347.
45. Szayna M, Doyle ME, Betkey JA, Holloway HW, Spencer RG, Greig NH, et al,. (2000). Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141: 1936-1941. (Pubitemid 32274340)
46. Triplitt C, Defronzo RA, (2006). Exenatide: first-in-class incretin mimetic for the treatment of type 2 diabetes mellitus. Expert Rev Endocrinol Metab 3: 329-341.
47. Yamamoto Y, Tsutsumi Y, Yoshioka Y, Nishibata T, Kobahashi K, Okamoto T, et al,. (2003). Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity. Nat Biotechnol 21: 546-552. (Pubitemid 36532020)
48. Youn YS, Jung JY, Oh SH, Yoo SD, Lee KC, (2006). Improved intestinal delivery of salmon calcitonin by Lys18-amino specific PEGylation, Stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy. J Control Rel 114: 334-342. (Pubitemid 44310815)
49. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, et al,. (1999). Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48: 1026-1034. (Pubitemid 29226349)